CLAIMS

20

- 1. A method for treating a non-microbial inflammatory skin condition, comprising administering a topical formulation comprising at least one imidazole or a dermatologically acceptable salt thereof, and a determatologically acceptable carrier to an individual in need thereof.
- 2. The method of claim 1 wherein the imidazole is selected from the group consisting of miconazole, ketoconazole, econazole and isoconazole.
- 3. The method of claim 1, wherein the imidazole is miconazole nitrate.
 - 4. The method of claim 1 wherein the imidazole is present in said formulation in an amount of about 0.1% to about 10.0% based on total weight of said formulation.
- 5. The method of claim 4 wherein the amount of the imidazole is about 0.25% to about 2.0%.
 - 6. The method of claim 1, wherein the inflammatory skin condition is selected from the group consisting of dry skin, severe dry skin, dermatitis, psoriasis, eczema, xerosis, terosis, ichthyosis, epidermolytic hyperkeratosis, infantile seborrhoeic dermatitis, atopic dermatitis, chronic dermatitis, keratoses, pruritis, cradle cap, scales, fresh stretch marks, dermatoses, burns and erythema.
- 7. The method of claim 1, wherein the inflammatory skin condition is dermatitis.
 - 8. The method of claim 1, wherein the inflammatory skin condition is ichthyosis.
 - 9. The method of claim 1, wherein the inflammatory skin condition is eczema.
- 30 10. The method of claim 1, wherein the inflammatory skin condition is psoriasis.
 - 11. The method of claim 1, wherein the carrier is petrolatum.

20

25

30

- 12. The method of claim 1, wherein the carrier is present in said formulation in an amount of about 90% to about 99.9% based on total weight of said formulation.
- 13. A method for treating a non-microbial inflammatory skin condition, comprising administering a topical formulation comprising a zinc compound, at least one imidazole or a dermatologically acceptable salt thereof, and a determatologically acceptable carrier to an individual in need thereof.
- 10 14. The method of claim 13 wherein the imidazole is selected from the group consisting of miconazole, ketoconazole, econazole and isoconazole.
 - 15. The method of claim 13, wherein the imidazole is miconazole nitrate.
- 16. The method of claim 13 wherein the imidazole is present in said formulation in an amount of about 0.1% to about 10.0% based on total weight of said formulation.
 - 17. The method of claim 16 wherein the amount of the imidazole is about 0.25% to about 2.0%.
 - 18. The method of claim 13, wherein the inflammatory skin condition is selected from the group consisting of dry skin, severe dry skin, dermatitis, psoriasis, eczema, xerosis, terosis, ichthyosis, epidermolytic hyperkeratosis, infantile seborrhoeic dermatitis, atopic dermatitis, chronic dermatitis, keratoses, pruritis, cradle cap, scales, fresh stretch marks, dermatoses, burns and erythema.
 - 19. The method of claim 13, wherein the inflammatory skin condition is dermatitis.
 - 20. The method of claim 13, wherein the inflammatory skin condition is ichthyosis.
 - 21. The method of claim 13, wherein the inflammatory skin condition is eczema.
 - 22. The method of claim 13, wherein the inflammatory skin condition is psoriasis.

WO 2005/041955 PCT/US2004/034486

34

- 23. The method of claim 13, wherein the carrier is petrolatum.
- 24. The method of claim 13, wherein the carrier is present in said formulation in an amount of about 60% to about 99.65% based on total weight of said formulation.
- The composition of claim 13, wherein the dermatologically absorbable zinc compound is selected from the group consisting of: zinc acetate, zinc bacitracin, bromide, zinc caprylate, zinc chloride, zinc citrate, zinc fluoride, zinc formate, zinc glycinate, zinc iodate, zinc lactate, zinc nitrate, zinc nitrite, zinc oleate, zinc oxalate, oxide, zinc permanganate, zinc peroxide, zinc. phenolsulfonate, zinc zinc phosphate, propionate, zinc zinc ricinoleate, zinc pyrophosphate, salicylate, zinc selenate, zinc silicate, zinc selenide, zinc sulfate, zinc stearate, zinc sulfide, zinc tannate, zinc tartrate, zinc valerate, zinc peptides, and zinc protein complexes.

15

20

25

30

- 26. The method of claim 13, wherein said zinc compound is present in said formulation in an amount of about 0.25% to about 30% based on total weight of said formulation.
- 27. A method for treating a non-microbial inflammatory skin condition, comprising administering a topical formulation comprising zinc oxide, miconazole or a dermatologically acceptable salt thereof, and petrolatum to an individual in need thereof.
- 28. A method of enhancing the transdermal penetration of a transdermally administrable chemical comprising administering to the skin at least one transdermally administrable chemical and a transdermal penetration enhancing amount of at least one imidazole.